Original Title: Pembrolizumab en pacientes con carcinoma renal de células claras

Authors' recommendations: Moderate-quality evidence shows that using pembrolizumab after nephrectomy due to clear-cell renal cell carcinoma, oligometastatic or with locoregional invasion, may potentially yield a higher net benefit. This is due to an improved overall survival and disease-free survival when compared with using tyrosine kinase inhibitors or placebo. Moderate-quality evidence shows that using pembrolizumab in combination with axitinib or lenvatinib as table metastatic clear-cell renal-cell carcinoma with favorable risk factors, may potentially yield a negative benefit, since it is associated with impaired overall survival when compared with the recommended therapies and other choices suggested by the Argentine Society of Clinical Oncology. Additionally, more grade three or higher adverse effects were observed in patients receiving pembrolizumab in combination with axitinib or lenvatinib. Low-quality evidence shows that pembrolizumab in combination with lenvatinib as first line therapy for patients with intermediate/high-risk unresectable metastatic clear-cell renal-cell carcinoma may yield a significant net benefit since it improves overall survival and progression-free survival, although with a higher number of adverse events. However, low-quality evidence suggest that pembrolizumab when compared with nivolumab in combination with cabozantinib in the same patient group, may yield a negative net benefit since it is associated with a lower overall survival with quality of life impairment and a higher number of serious adverse events. Low-quality evidence shows that using pembrolizumab in combination with axitinib as first line therapy with intermediate/high-risk unresectable metastatic clear-cell renal-cell carcinoma may yield a lower net benefit. Although there is improved overall survival and progression-free survival, a higher number of adverse events was observed. However, low-quality evidence suggests that using pembrolizumab when compared with nivolumab in combination with cabozantinib in the same patient group may yield a negative net benefit; since it is associated with a shorter overall survival with impaired quality of live and higher number of serious adverse events

Project Status: Completed

Year Published: 2022

URL for published report: https://www.iecs.org.ar/publicacion/?id=23095

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: Argentina

Organisation Name: Institute for Clinical Effectiveness and Health Policy

Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA

Contact Name: info@iecs.org.ar

Contact Email: info@iecs.org.ar

Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)